Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $16.71.
A number of equities analysts have recently commented on the stock. Roth Capital set a $27.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 11th. Jefferies Group LLC reiterated a “hold” rating and set a $14.00 price target (down previously from $16.00) on shares of Sucampo Pharmaceuticals in a report on Saturday, March 11th. Maxim Group set a $19.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 11th. ValuEngine lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Mizuho reiterated a “buy” rating and set a $16.00 price target on shares of Sucampo Pharmaceuticals in a report on Monday, March 6th.
Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 1.04% on Friday, reaching $9.75. 304,139 shares of the company traded hands. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $17.55. The company has a market capitalization of $453.02 million, a PE ratio of 16.25 and a beta of 1.40. The stock has a 50-day moving average of $10.24 and a 200 day moving average of $11.60.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by $0.05. The company had revenue of $56.30 million during the quarter, compared to analyst estimates of $54.15 million. Sucampo Pharmaceuticals had a net margin of 11.36% and a return on equity of 43.27%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.21 EPS. On average, equities analysts forecast that Sucampo Pharmaceuticals will post $1.04 EPS for the current year.
WARNING: “Brokerages Set Sucampo Pharmaceuticals, Inc. (SCMP) Target Price at $16.71” was first posted by BBNS and is owned by of BBNS. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://baseballnewssource.com/markets/sucampo-pharmaceuticals-inc-scmp-receives-16-71-average-price-target-from-brokerages-updated/985254.html.
A number of institutional investors have recently made changes to their positions in the company. Louisiana State Employees Retirement System purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $111,000. Envestnet Asset Management Inc. purchased a new position in shares of Sucampo Pharmaceuticals during the fourth quarter worth $115,000. Karp Capital Management Corp purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $119,000. Capstone Asset Management Co. purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $133,000. Finally, New York State Teachers Retirement System purchased a new position in shares of Sucampo Pharmaceuticals during the first quarter worth $137,000. 57.00% of the stock is owned by institutional investors and hedge funds.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.